Evidence map›Paper›PMID 31355178›Full record

ReviewFrontiers in chemistry2019

Polydopamine-Based Nanocarriers for Photosensitizer Delivery.

Yuxuan Xiong, Zushun Xu, Zifu Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Yuxuan XiongDepartment of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.
Zushun XuKey Laboratory for the Green Preparation and Application of Functional Materials, Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Ministry of Education, Hubei University, Wuhan, China.
Zifu LiDepartment of Nanomedicine and Biopharmaceuticals, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Photodynamic therapy (PDT) has emerged as a non-invasive modality for treating tumors while a photosensitizer (PS) plays an indispensable role in PDT. Nevertheless, free PSs are limited by their low light stability, rapid blood clearance, and poor water solubility. Constructing a nanocarrier delivering PSs is an appealing and potential way to solve these issues. As a melanin-like biopolymer, polydopamine (PDA) is widely utilized in biomedical applications (drug delivery, tissue engineering, and cancer therapy) for its prominent properties, including favorable biocompatibility, easy preparation, and versatile functionality. PDA-based nanocarriers are thus leveraged to overcome the inherent shortcomings of free PSs. In this Mini-Review, we will firstly present an overview on the recent developments of PDA nanocarriers delivering PSs. Then, we introduce three distinctive strategies developed to combine PSs with PDA nanocarriers. The advantages and disadvantages of each strategy will be discussed. Finally, the current challenges and future opportunities of PDA-based PS nanocarriers will also be addressed.

Indexed as

drug deliverynanocarriersphotodynamic therapyphotosensitizerspolydopamine

Identifiers

PMID31355178
PMCPMC6639787

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.